| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | selumetinib:MK-2206 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.019 | 0.8 |